Company / SG&A Expense
enGene Holdings Inc. SG&A Expense History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$28.7M
FY2025
5-year range
$4.0M / $28.7M
FY2022-FY2025
Trend
+19.6%
vs FY2024
Sector context
#186 of 212
Health Care
What the data says
enGene Holdings Inc.'s sg&a expense of $29M is lower than 88% of companies in the Health Care sector (FY2025). SG&A Expense has increased for 3 consecutive years, from $4M in FY2022 to $29M in FY2025.
Based on SEC 10-K filings.
$29M in FY2025 with a 3-year CAGR of +93.5%.
Increased from $10M to $29M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +93.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 12% in Health CareTop 12% of 212This company $28.7M Sector average $722.9M
▼
-96.0% below sector average
Key checks
Key Insights
- enGene Holdings Inc.'s sg&a expense has grown for 3 consecutive years.
- 3-year CAGR of +93.5%, indicating consistent growth.
- In FY2025, sg&a expense increased 19.6% year-over-year.
- Ranks #186 out of 212 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $28.7M | +19.6% |
| FY2024 | $24.0M | +149.8% |
| FY2023 | $9.6M | +142.5% |
| FY2022 | $4.0M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026